GlassScriptPhysician profile
David M Lorah
NPI 1780767996
$2,370.78
in general payments reported to CMS, 2019-2025
25 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $156 · 2021: $266 · 2022: $350 · 2023: $618 · 2024: $380 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $428.61 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $400.21 | 2021-2025 | |
| Pfizer INC. | $226.34 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $193.31 | 2019-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $181.77 | 2019-2024 | Airsupra, Bevespi Aerosphere, Farxiga |
| Exact Sciences Corporation | $133.07 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $106.06 | 2019-2025 | Veozah |
| Allergan, INC. | $89.02 | 2019-2022 | |
| Amarin Pharma, INC. | $88.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $77.38 | 2019-2025 | Vaxelis, Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $51.16 | 2019-2020 | |
| Eisai INC. | $47.14 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $46.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.59 | 2022-2024 | |
| Lilly USA, LLC | $39.78 | 2021-2024 | Mounjaro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $30.61 | 2023 | |
| Novo Nordisk INC | $26.53 | 2021 | |
| Becton, Dickinson and Company | $26.44 | 2025 | Bd Onclarity |
| Shockwave Medical, INC | $25.17 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Mimedx Group, INC. | $20.91 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.91 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.73 | 2024 | |
| Nestle Healthcare Nutrition INC. | $18.74 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.51 | 2019 | |
| Hologic Sales and Service, LLC | $13.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lorah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.